









Markets
/
Stocks
/
nasdaq-nnvc
/

NanoViricides Inc

NNVC

0.880USD

+0.030+3.53%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

15.45MMarket Cap

LossP/E TTM



NanoViricides Inc

0.880

+0.030+3.53%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of NanoViricides Inc

Currency: USD Updated: 2026-02-06

Key Insights

NanoViricides Inc's fundamentals are relatively weak, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 180 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 6.33.In the medium term, the stock price is expected to trend down.Despite a very weak stock market performance over the past month, the company shows strong technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

NanoViricides Inc's Score

Industry at a Glance

Industry Ranking

180 / 392

Overall Ranking

337 / 4521

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Positive

NanoViricides Inc Highlights

StrengthsRisks

NanoViricides, Inc. is a clinical-stage company. The Company is engaged in developing a class of drugs that it calls nanoviricides, using a platform technology based on the application of nanomedicine technologies to the complex issues of viral diseases. Its lead drug candidate is NV-387, a broad-spectrum antiviral drug that has demonstrated activity in lethal lung infection animal model studies of Coronavirus (COVID), Respiratory Syncytial Virus, Influenza, Orthopoxvirus model for Smallpox and MPox, and even in a humanized mice model for Measles. It is focused on advancing Phase II clinical trials. Its other advanced drug candidate is NV-HHV-1 for the treatment of Shingles rash. Its NV-CoV-2 and NV-CoV-2-R are drug candidates for the treatment of COVID. Its portfolio also includes NV-HIV-1, a novel mechanism Anti-HIV Drug Candidate. Its other drug candidates include treatment for viral infections, including Dengue viruses, Ebola viruses, among others.

Overvalued

The company’s latest PE is -1.75, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 1.44M shares, decreasing 12.23% quarter-over-quarter.

Held by James Simons

Star Investor James Simons holds 210.50K shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.42.

Analyst Rating

Based on 1 analysts

Buy

Current Rating

6.333

Target Price

+645.10%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of NanoViricides Inc is 5.52, ranking 352 out of 392 in the Biotechnology & Medical Research industry. Its financial status is weak, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

5.52

Change



Financials

2.40

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.40

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

4.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

6.75

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.03

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

NanoViricides Inc's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of NanoViricides Inc is 6.43, ranking 281 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is -1.75, which is -26.53% below the recent high of -1.29 and -132.90% above the recent low of -4.08.

Score

Industry at a Glance

Previous score

6.43

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 180/392

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of NanoViricides Inc is 8.00, ranking 164 out of 392 in the Biotechnology & Medical Research industry. The average price target is 7.00, with a high of 7.00 and a low of 7.00.

Score

Industry at a Glance

Previous score

8.00

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 1 analysts

Buy

Current Rating

6.333

Target Price

+645.10%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

542

Total

Median

Average

Company name

Ratings

Analysts

NanoViricides Inc

NNVC

CRISPR Therapeutics AG

CRSP

argenx SE

ARGX

IQVIA Holdings Inc

IQV

Beigene Ltd

ONC

Intellia Therapeutics Inc

NTLA

...

109

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of NanoViricides Inc is 6.53, ranking 229 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 1.13 and the support level at 0.74, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.39

Change

0.14

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(1)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.041

Sell

RSI(14)

31.145

Neutral

STOCH(KDJ)(9,3,3)

7.870

Oversold

ATR(14)

0.063

High Vlolatility

CCI(14)

-102.810

Sell

Williams %R

91.667

Oversold

TRIX(12,20)

-0.968

Sell

StochRSI(14)

51.924

Buy

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

0.915

Sell

MA10

0.978

Sell

MA20

1.065

Sell

MA50

1.160

Sell

MA100

1.332

Sell

MA200

1.401

Sell

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of NanoViricides Inc is 3.00, ranking 197 out of 392 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 6.67%, representing a quarter-over-quarter decrease of 12.99%. The largest institutional shareholder is The Vanguard, holding a total of 605.58K shares, representing 2.81% of shares outstanding, with 13.96% decrease in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

The Vanguard Group, Inc.

Star Investors

605.58K

+18.64%

Theracour Pharma, Inc.

470.96K

Renaissance Technologies LLC

Star Investors

210.50K

+88.96%

Geode Capital Management, L.L.C.

159.43K

+0.91%

BlackRock Institutional Trust Company, N.A.

158.75K

Susquehanna International Group, LLP

52.22K

State Street Investment Management (US)

41.91K

Jawadakar (Makarand)

41.54K

Rokita (Theodore)

41.04K

+0.07%

Zucker (Brian)

39.79K

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. No risk assessment score is currently available for NanoViricides Inc. The Biotechnology & Medical Research industry's average is 3.38. The company's beta value is 1.33. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.